Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Male Sprague-Dawley rats; numbers not stated in the abstract
- Dose used in the study
- No palmitoylethanolamide was given; synthetic oleoyl glycine 1 to 30 mg/kg intraperitoneally
- Duration
- Not stated in the abstract
- What was measured
- Place aversion from naloxone-precipitated morphine withdrawal; morphine place preference; brain levels of oleoyl glycine, 2-AG, anandamide, oleoylethanolamide and palmitoylethanolamide
What the authors reported
Oleoyl glycine at 1 and 5 mg/kg blocked the aversive effect of morphine withdrawal; AM251 (a CB1 antagonist) reversed this but MK886 (a PPAR-alpha antagonist) did not, and morphine reward was unchanged. Withdrawal raised oleoyl glycine in the nucleus accumbens but did not change 2-AG, anandamide, oleoylethanolamide or palmitoylethanolamide in any region.
Limits of this study
A rat study of a different fatty acid amide; palmitoylethanolamide was only measured and did not change. It cannot show effect in people. Funding and conflicts not stated in the abstract.
Source
PubMed 30993360 · doi:10.1007/s00213-019-05237-9
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.